Three-year follow-up from a randomised controlled trial of a single intra-articular polyacrylamide hydrogel injection in subjects with knee osteoarthritis
Authors' conclusion
A single 6 mL IA injection of 2.5% iPAAG appears to be safe and effective in providing sustained symptom relief for up to 3 years in individuals with knee OA.
Study context
- Population
- Adults with moderate-to-severe knee osteoarthritis (OA) who received 2.5% iPAAG in an randomised controlled trial (RCT) vs hyaluronic acid (HA)91 entered extension
- Participants
- 119 adults
Methodological details3-year extension, single-group follow-up
- 3-year extension
- Single-group follow-up
Primary result
As reported in the abstract
WOMAC pain (0-100), mean change from baseline · up to year 3
Mean change in WOMAC pain at year 3 (single-group, 2.5% iPAAG)
−13.1
95% CI −17.9 to −8.4p<0.0001
Safety
| Outcome | Values |
|---|---|
| AEs between 1-year and 3-year visits · years 1–3 | 2.5% iPAAG 29.8% · AEs reported 50 |
- Adverse events (AEs) between 1-year and 3-year visits: none assessed as related to 2.5% iPAAG
Original publication
Three-year follow-up from a randomised controlled trial of a single intra-articular polyacrylamide hydrogel injection in subjects with knee osteoarthritis. Clin Exp Rheumatol. Published 23 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →